A new vaccine holds great promise to sufferers of allergy rhinitis (hay fever)

A study conducted by Johns Hopkins University's Asthma and Allergy Center on a new vaccine made by California-based Dynavax Technologies holds great promise for up to 40 million Americans suffer from hay fever.

A short course of immunotherapy that reduces allergic symptoms over an extended period of time will significantly improve the quality of life for many people. The vaccine reduced symptoms of sneezing, runny nose and eyes, and itchy ears and throats by 60 percent on average.